Heart in Diabetes 9th Annual Heart in Diabetes Conference 2025

Heart in Diabetes 9th Annual Heart in Diabetes Conference 2025 Description Include: 72 Videos (.mp4)  no PDFs Target Audience: cardiologists, endocrinologists, and nephrologists   Information: 1. Overview The Heart in Diabetes 9th Annual Conference 2025 provides a comprehensive clinical exploration of the intersection between cardiovascular, renal, and metabolic diseases. The program delivers expert insights into managing resistant hypertension, chronic kidney disease, heart failure, obesity, and dyslipidemia, emphasizing the latest pharmacological advancements such as GLP-1 receptor agonists, SGLT2 inhibitors, and novel lipid-lowering therapies. Course Date: 2025 2. Learning Objectives Evaluate the pathophysiology and clinical management of cardiorenal metabolic diseases, including resistant hypertension and diabetic cardiomyopathy. Implement guideline-directed medical therapies using GLP-1 RAs, SGLT2 inhibitors, and novel MRAs to optimize cardio-renal protection in patients with diabetes. Analyze the systemic impact of sleep disorders, hypercortisolism, and women-specific risk factors on cardiovascular and metabolic health. Assess the latest cardiovascular outcome trials (CVOTs) and integrate emerging lipid-lowering treatments targeting ApoB and CETP into clinical practice. Apply digital health technologies, intensive lifestyle interventions, and multidisciplinary approaches to manage complex cases involving obesity and heart failure. 3. Target Audience Best for cardiologists, endocrinologists, and nephrologists who want updates on cardiorenal metabolic therapies, clinical trials, and obesity. Day 1 # Title Length 1 Epidemiology and Pathophysiology of Resistant Hypertension and CKD Treatment 18:08 2 Management of Chronic Kidney Disease With or Without Albuminuria 20:13 3 Emerging Approaches to the Treatment of Resistant Hypertension 19:25 4 Case Presentation – Treatment Resistant Hypertension 29:36 5 Cortisol – Impact on Endocrinology & Metabolism 19:13 6 Cortisol’s Impact on the Kidney-BP-Bone 20:04 7 Cardiovascular Implications of Hypercortisolism 17:48 8 Panel Discussion and Q&A – Cortisol & Cardiorenalmetabolic Diseases 09:11 9 MASLD and MASH – Pathophysiology, Diagnosis and Management 21:32 10 Sleep Health: Implications for Obesity and Diabetes Risk 22:48 11 Sleep and Cardiovascular Risk 19:08 12 Panel Discussion and Q&A – Sleep Disorders in Cardiometabolism 08:25 13 Prediabetes: What’s a Clinician to Do? 21:05 14 Unraveling the Connection: Diabetes and Dementia 18:02 15 Pulmonary Disorders in Diabetes – Implications for Heart Disease 20:30 16 Diabetes and Cardiovascular Disease in Older Adults 20:10 17 Panel Discussion and Q&A – Diabetes Comorbidities 10:56 18 Implementing Guideline-Directed Medical Therapy: Stakeholder-Identified Barriers and Facilitators 18:21 19 Population Health Approaches to Accelerate the Prevention of CVD: Moving from Action to Impact 15:57 20 Panel Discussion and Q&A – Implementation Science in Practice 11:09 21 Dyslipidemia in Women Across a Lifetime Approach to Management 21:24 22 Sex Hormones and Anthropometric Measures & Heart Failure Risk in Women 19:12 23 Panel Discussion and Q&A – Women’s Health 08:28 24 Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone or In Combination With SGLT2 Inhibitors in T2D 15:22 25 Optimal Strategy for Heart Failure Screening Among Adults With Diabetes Without ASCVD – A Pooled Cohort Analysis 14:57 26 Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With T2D and CKD 13:15 27 Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Chronic Kidney Disease 15:38 28 Panel Discussion and Q&A – Circulation 36:51 Day 2 # Title Length 1 Current Trends in Epidemiology of Heart Failure – USA 19:19 2 Diabetic Cardiomyopathy: Mechanisms and Future Directions 15:25 3 Bromocriptine in the Treatment of Peripartum Cardiomyopathy: Is It Ready for Prime Time? 18:15 4 Proper Medical Management of HFpEF in 2025 22:35 5 Panel Discussion and Q&A – Heart Failure: The Now & The New 21:17 6 GLP1-RA, Obesity & Diabetes: Mechanisms of Cardiovascular Protection 22:06 7 Cardio-Kidney Protection With Incretin Therapies 12:38 8 Incretins: Today and Tomorrow 20:39 9 Panel Discussion and Q&A – Current & Future Role of Incretin Therapy 16:05 10 Diabetes and Cardiovascular Disease: The Evolution of CV Outcomes Assessment of Antihyperglycemic Medications 27:06 11 My Personal Journey to HoFH Diagnosis 14:59 12 From Rare to the Very Common – Role of Genetics in Lipid Disorders 16:24 13 CETPi – Where Might They Fit Into Clinical Practice 09:11 14 Using ApoB in Clinical Practice – From Risk Assessment to Treatment Targets 16:21 15 Obesity and Dyslipidemia – Can We Finally Break the Cycle With Dual Agonists 09:53 16 The Epidemiology and Pathophysiology of Cardio-Kidney-Metabolic Diseases 17:14 17 Unmet Needs in CKD in T1D and Challenges in CKD Beyond Diabetes 22:04 18 Finerenone Across the Stages of Heart Failure: From Prevention to Treatment 18:22 19 Panel Discussion and Q&A – Cardio-Renal Protection in CKM Diseases 17:16 20 Digital Health Technologies for Cardiometabolic Disease & Diabetes 21:21 21 Food Is Medicine Strategies for Nutrition Security & Cardiometabolic Health Equity 20:38 22 Intensive Lifestyle Intervention, Cardiac Biomarkers, and Cardiovascular Outcomes in Diabetes 13:18 23 Racial Differences in Diabetic Cardiomyopathy: Results From the ARISE-HF Study 09:19 24 Panel Discussion and Q&A – JACC 26:57 25 Technology in the Management of Diabetes: Addressing Its Role in Comorbidities 20:28 26 SGLT2 Inhibitors: Reconsidering, Repurposing, Reimagining 21:28 27 Panel Discussion and Q&A – Diabetes Management & Technology 08:27   Day 3 # Title Length 1 Management of Complex Cases: Obesity and Heart Failure 23:09 2 The Edema Dilemma – A Case of Diabetes Mellitus, HFpEF, Obesity, CKD and Proteinuria 21:19 3 CRM Management of Complex Cases 17:48 4 The Lancet Commission on Obesity 19:38 5 Obesity: Role of Medical Management 19:53 6 Management of Obesity Addressing Lean Mass Preservation 23:02 7 Panel Discussion and Q&A – Obesity 07:17 8 Do ACEI/ARB Still Have a Role in the Era of SGLT2, MRA and GLP1A? 15:38 9 The Role of Diastolic & Pulse Pressure in CKD & CVD – Management Considerations 18:37 10 Aldosterone: The Forgotten Hormone in Hypertension 26:14 11 Panel Discussion and Q&A – The Kidney and Hypertension 13:07 12 Combination Treatment to Improve Heart and Kidney Outcomes in Diabetic Kidney Disease 19:04 13 The Latest Heart Disease & Stroke Statistics: US & Global Data from the American Heart Association 17:48 14 Appropriate Cardiac Intervention in the Diabetes Cardiorenal & Metabolic Medicine Patient 20:17 15 Serum Lipoproteins & Coronary Atherosclerosis in Asymptomatic U.S. Adults Without Traditional Risk Factors 20:08 16 Cardiovascular Outcome Trials Update 17:31 17 Panel Discussion and Q&A – ASCVD 25:20